The DOI matches its Crossref record; 93 of the 94 references it cites were found in a registry or an index.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses
Open accessAbstract
We show that DNA methyltransferase inhibitors (DNMTis) upregulate immune signaling in cancer through the viral defense pathway. In ovarian cancer (OC), DNMTis trigger cytosolic sensing of double-stranded RNA (dsRNA) causing a type I interferon response and apoptosis. Knocking down dsRNA sensors TLR3 and MAVS reduces this response 2-fold and blocking interferon beta or its receptor abrogates it. Upregulation of hypermethylated endogenous retrovirus (ERV) genes accompanies the response and ERV overexpression activates the response. Basal levels of ERV and viral defense gene expression significantly correlate in primary OC and the latter signature separates primary samples for multiple tumor types from The Cancer Genome Atlas into low versus high expression groups. In melanoma patients treated with an immune checkpoint therapy, high viral defense signature expression in tumors significantly associates with durable clinical response and DNMTi treatment sensitizes to anti-CTLA4 therapy in a pre-clinical melanoma model.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The IFN-I response could also expose the tumor cells to surveillance by the immune system96, 97.”
From The role of retrotransposable elements in ageing and age-associated diseases (2021) · cites this paper as [97]
The cited source says what the claim attributes to it.
In the citing paper
“multiple studies have shown that DNA demethylating agents among other epigenetic modulators can induce a type I IFN response in cancer cells through the de-repression of endogenous retroviruses (ERVs) and activation of the MDA5-MAVS pathway38–40.”
From Epigenetic state determines the in vivo efficacy of STING agonist therapy (2023) · cites this paper as [38]
The cited source says what the claim attributes to it.
In the citing paper
“DAC treatment could induce expression of retrotransposons normally silenced by DNA methylation, which could also augment tumor immunogenicity10–14,99.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“inactivated typical enhancers were associated with collagen fibril organization and chemotaxis GO terms and were enriched for binding motifs of immune-related TFs, including STAT1 (Fig. 2a, b)12,13.”
From Multi-omic analysis of hepatocellular carcinoma reveals aberrant cis-regulatory changes and dysregulated retrotransposons with prognostic potential (2025) · cites this paper as [12]
Experimental — accuracy not yet measuredIn the citing paper
“inhibiting EZH2 activity can either positively or negatively influence tumour-specific immune responses by modulating both tumour immunogenicity and the function of infiltrating T-cells, NK-cells and macrophages 196 .”
From The roles of DNA, RNA and histone methylation in ageing and cancer (2019) · cites this paper as [196]
In the citing paper
“derepression of endogenous retroviral elements coupled to robust type I and type III IFN signaling”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chiappinelli et al., 2015
In the citing paper
“Certainly, this dual epigenetic targeting may influence additional antiproliferative mechanisms and further enhance antitumor surveillance by the immune system (Chiappinelli et al., 2015).”
From HDACs and the epigenetic plasticity of cancer cells: target the complexity (2022) · cites this paper as Chiappinelli et al., 2015
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationThe blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Self-citationSafety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Self-citationSafety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Self-citationCancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474
ConsensusClusterPlus: a class discovery tool with confidence assessments and item tracking
Wilkerson, M. D., & Hayes, D. N. (2010) · Bioinformatics · doi:10.1093/bioinformatics/btq170 · Cited by 5,645
Flagged first, then by citations
1 of the 94 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 401–500 of 1,003
Marwitz, S., Scheufele, S., Perner, S., Reck, M., Ammerpohl, O., & Goldmann, T. (2017) · Clinical Epigenetics · doi:10.1186/s13148-017-0354-2 · Cited by 68
HIF regulates multiple translated endogenous retroviruses: Implications for cancer immunotherapy
Jiang, Q., Braun, D. A., Clauser, K. R., Ramesh, V., Shirole, N. H., Duke-Cohan, J. E., Nabilsi, N., Kramer, N. J., Forman, C., Lippincott, I. E., et al. (2025) · Cell · doi:10.1016/j.cell.2025.01.046 · Cited by 68
Immune Mechanisms in Myelodysplastic Syndrome
Glenthøj, A. B., Ørskov, A. D., Hansen, J., Hadrup, S. R., O'Connell, C. L., & Grønbæk, K. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17060944 · Cited by 69
Endogenous Retroviruses Transcriptional Modulation After Severe Infection, Trauma and Burn
Tabone, O., Mommert, M., Jourdan, C., Cerrato, E., Legrand, M. M., Lepape, A., Allaouchiche, B., Rimmelé, T., Pachot, A., Monneret, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2018.03091 · Cited by 70
Bufalieri, F., Caimano, M., Severini, L. L., Basili, I., Paglia, F., Sampirisi, L., Loricchio, E., Petroni, M., Canettieri, G., Santoro, A., et al. (2020) · Cancers · doi:10.3390/cancers12020321 · Cited by 65
Endogenous retroviruses in development and health
Wang, J., Lu, X., Zhang, W., & Liu, G. (2023) · Trends in Microbiology · doi:10.1016/j.tim.2023.09.006 · Cited by 72
TNRC18 engages H3K9me3 to mediate silencing of endogenous retrotransposons
Zhao, S., Lu, J., Pan, B., Fan, H., Byrum, S. D., Xu, C., Kim, A., Guo, Y., Kanchi, K., Gong, W., et al. (2023) · Nature · doi:10.1038/s41586-023-06688-z · Cited by 65
Brennan, K., Koenig, J. L., Gentles, A. J., Sunwoo, J. B., & Gevaert, O. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.02.025 · Cited by 67
Gene-Specific Targeting of DNA Methylation in the Mammalian Genome
Urbano, A., Smith, J., Weeks, R. J., & Chatterjee, A. (2019) · Cancers · doi:10.3390/cancers11101515 · Cited by 67
Ohtani, H., Ørskov, A. D., Helbo, A. S., Gillberg, L., Liu, M., Zhou, W., Ungerstedt, J. S., Hellström‐Lindberg, E., Sun, W., Liang, G., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-1696 · Cited by 67
Mulholland, C. B., Nishiyama, A., Ryan, J., Nakamura, R., Yiğit, M., Glück, I. M., Trummer, C., Qin, W., Bartoschek, M. D., Traube, F. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19603-1 · Cited by 74
Xiong, H., Ma, X., Wang, X., Su, W., Wu, L., Zhang, T., Xu, Z., & Sun, Z. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100007 · Cited by 68
Chernyavskaya, Y., Mudbhary, R., Zhang, C., Tokarz, D. A., Jacob, V., Gopinath, S., Sun, X., Wang, S., Magnani, E., Madakashira, B. P., et al. (2017) · Development · doi:10.1242/dev.147629 · Cited by 67
Izquierdo‐Bouldstridge, A., Bustillos, A., Bonet-Costa, C., Aribau-Miralbés, P., García-Gomis, D., Dabad, M., Esteve‐Codina, A., Pascual‐Reguant, L., Peiró, S., Esteller, M., et al. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx746 · Cited by 69
Zhang, G., Jiang, P., Tang, W., Wang, Y., Qiu, F., An, J., Zheng, Y., Wu, D., Zhou, J., Neculai, D., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.10.043 · Cited by 66
The tumor-intrinsic role of the m 6 A reader YTHDF2 in regulating immune evasion
Xiao, S., Ma, S., Sun, B., Pu, W., Duan, S., Han, J., Ya-qun, H., Zhang, J., Peng, Y., He, C., et al. (2024) · Science Immunology · doi:10.1126/sciimmunol.adl2171 · Cited by 69
Stress and Non-Stress Roles of Inflammatory Signals during HSC Emergence and Maintenance
Clapes, T., Lefkopoulos, S., & Trompouki, E. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00487 · Cited by 66
Epigenetic modulation in cancer immunotherapy
Gallagher, S. J., Shklovskaya, E., & Hersey, P. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.006 · Cited by 68
Wang, M., Liu, Y., Cheng, Y., Wei, Y., & Wei, X. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2018.12.002 · Cited by 66
All I's on the RADAR : role of ADAR in gene regulation
Shevchenko, G., & Morris, K. V. (2018) · FEBS Letters · doi:10.1002/1873-3468.13093 · Cited by 67
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance
Olino, K. L., Park, T. S., & Ahuja, N. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.001 · Cited by 65
Liu, M., Zhang, L., Li, H., Hinoue, T., Zhou, W., Ohtani, H., El-Khoueiry, A. B., Daniels, J. R., O'Connell, C. L., Dorff, T. B., et al. (2018) · Hepatology · doi:10.1002/hep.30091 · Cited by 65
Self-citationCriscuolo, D., Morra, F., Giannella, R., Visconti, R., Cerrato, A., & Celetti, A. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1089-z · Cited by 64
Y RNAs are conserved endogenous RIG-I ligands across RNA virus infection and are targeted by HIV-1
Vabret, N., Najburg, V., Solovyov, A., Gopal, R., McClain, C. B., Šulc, P., Balan, S., Rahou, Y., Beauclair, G., Chazal, M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104599 · Cited by 61
Transcriptional Selectivity of Epigenetic Therapy in Cancer
Sato, T., Cesaroni, M., Chung, W., Panjarian, S. B., Tran, A., Madžo, J., Okamoto, Y., Zhang, H., Chen, X., Jelı́nek, J., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0834 · Cited by 64
Panda, A., Betigeri, A. M., Subramanian, K., Ross, J. S., Pavlick, D. C., Ali, S. M., Markowski, P. A., Silk, A. W., Kaufman, H. L., Lattime, E. C., et al. (2017) · JCO Precision Oncology · doi:10.1200/po.17.00146 · Cited by 64
Human Endogenous Retroviruses (HERVs): Shaping the Innate Immune Response in Cancers
Alcazer, V., Bonaventura, P., & Depil, S. (2020) · Cancers · doi:10.3390/cancers12030610 · Cited by 70
Ramesh, V., Bayam, E., Cernilogar, F. M., Bonapace, I. M., Schulze, M., Riemenschneider, M. J., Schotta, G., & Götz, M. (2016) · Genes & Development · doi:10.1101/gad.284992.116 · Cited by 63
Tovy, A., Spiro, A., McCarthy, R. L., Shipony, Z., Aylon, Y., Allton, K. L., Ainbinder, E., Furth, N., Tanay, A., Barton, M. C., et al. (2017) · Genes & Development · doi:10.1101/gad.299198.117 · Cited by 64
Zhou, Y., Li, M., Xue, Y., Li, Z., Wen, W., Liu, X., Ma, Y., Zhang, L., Shen, Z., & Cao, X. (2019) · Cell Research · doi:10.1038/s41422-019-0193-0 · Cited by 63
Endogenous Retrovirus Activation as a Key Mechanism of Anti-Tumor Immune Response in Radiotherapy
Lee, A. K., Pan, D., Bao, X., Hu, M., Li, F., & Li, C. (2020) · Radiation Research · doi:10.1667/rade-20-00013 · Cited by 69
Zebularine elevates STING expression and enhances cGAMP cancer immunotherapy in mice
Lai, J., Fu, Y., Tian, S., Huang, S., Luo, X., Lin, L., Zhang, X., Wang, H., Lin, Z., Zhao, H., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.02.005 · Cited by 63
Xue, G., Zheng, N., Fang, J., Jin, G., Li, X., Dotti, G., Yi, Q., & Lu, Y. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.09.011 · Cited by 64
Huyghe, N. D., Benidovskaya, E., Stevens, P., & den Eynde, M. V. (2022) · Cancers · doi:10.3390/cancers14092241 · Cited by 65
Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas
Li, Y., Goldberg, E. M., Chen, X., Xu, X., McGuire, J. T., Leuzzi, G., Karagiannis, D., Tate, T., Farhangdoost, N., Horth, C., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.007 · Cited by 65
Schroeder, T. A., Rautenberg, C., Haas, R. R., Germing, U., & Kobbe, G. (2017) · International Journal of Hematology · doi:10.1007/s12185-017-2364-4 · Cited by 63
Leadem, B. R., Kagiampakis, I., WILSON, C. A., Cheung, T. K., Arnott, D. P., Trojer, P., Classon, M., Easwaran, H., & Baylin, S. B. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-1453 · Cited by 66
Self-citationJacobson, M. E., Wang-Bishop, L., Becker, K. W., & Wilson, J. T. (2018) · Biomaterials Science · doi:10.1039/c8bm01064a · Cited by 62
Immune signatures correlate with L1 retrotransposition in gastrointestinal cancersPreprint
Jung, H., Choi, J. K., & Lee, E. A. (2018) · Genome Research · doi:10.1101/gr.231837.117 · Cited by 62
Such, L., Zhao, F., Liu, D. H., Thier, B., Le‐Trilling, V. T. K., Sucker, A., Coch, C., Pieper, N., Howe, S., Bhat, H., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci131572 · Cited by 61
Shen, H., Zhang, W., Huang, Y., He, Y., Hu, G.-S., Wang, L., Peng, B., Jia, Y., Li, T., Rong, R., et al. (2021) · Advanced Science · doi:10.1002/advs.202004635 · Cited by 66
Papadatos-Pastos, D., Yuan, W., Pal, A., Crespo, M., Ferreira, A., Gürel, B., Prout, T., Ameratunga, M., Chénard-Poirier, M., Curcean, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004495 · Cited by 60
Tobiasson, M., Abdulkadir, H., Lennartsson, A., Katayama, S., Marabita, F., Paepe, A. D., Karimi, M., Krjutškov, K., Einarsdóttir, E., Grövdal, M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15807 · Cited by 64
Sun, W., Triche, T. J., Malvar, J., Gaynon, P. S., Sposto, R., Yang, X., Bittencourt, H. N. D. S., Place, A. E., Messinger, Y. H., Fraser, C., et al. (2018) · Blood · doi:10.1182/blood-2017-09-803809 · Cited by 62
Take two: Combining immunotherapy with epigenetic drugs to tackle cancer
Weintraub, K. (2016) · Nature Medicine · doi:10.1038/nm0116-8 · Cited by 62
Clinical update on hypomethylating agents
Duchmann, M., & Itzykson, R. (2019) · International Journal of Hematology · doi:10.1007/s12185-019-02651-9 · Cited by 60
Widespread and tissue-specific expression of endogenous retroelements in human somatic tissues
Larouche, J., Trofimov, A., Hesnard, L., Ehx, G., Zhao, Q., Vincent, K., Durette, C., Gendron, P., Laverdure, J., Bonneil, É., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00740-7 · Cited by 60
Role of Epigenetic Regulation in Plasticity of Tumor Immune Microenvironment
Yang, Y., & Wang, Y. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.640369 · Cited by 64
Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer.
Rajurkar, M., Parikh, A. R., Solovyov, A., You, E., Kulkarni, A. S., Chu, C., Xu, K. H., Jaicks, C., Taylor, M. S., Wu, C., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1117 · Cited by 61
Sources of Cancer Neoantigens beyond Single-Nucleotide Variants
Capietto, A.-H., Hoshyar, R., & Delamarre, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231710131 · Cited by 63
Recent advances in understanding antitumor immunity
Munhoz, R. R., & Postow, M. A. (2016) · F1000Research · doi:10.12688/f1000research.9356.1 · Cited by 70
Dying to Be Noticed: Epigenetic Regulation of Immunogenic Cell Death for Cancer Immunotherapy
Cruickshank, B. M., Giacomantonio, M., Marcato, P., McFarland, S. A., Pol, J. G., & Gujar, S. A. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00654 · Cited by 62
Borcherding, N. C., Kolb, R. H., Gullicksrud, J. A., Vikas, P., Zhu, Y., & Zhang, W. (2018) · Journal of Molecular Biology · doi:10.1016/j.jmb.2018.05.030 · Cited by 60
Klymenko, Y., & Nephew, K. P. (2018) · Cancers · doi:10.3390/cancers10090295 · Cited by 63
Reciprocal regulation of RIG-I and XRCC4 connects DNA repair with RIG-I immune signaling
Guo, G., Gao, M., Gao, X., Zhu, B., Huang, J., Tu, X., Kim, W., Zhao, F., Zhou, Q., Zhu, S., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22484-7 · Cited by 62
Switching Sides: How Endogenous Retroviruses Protect Us from Viral Infections
Badarinarayan, S. S., & Sauter, D. (2021) · Journal of Virology · doi:10.1128/jvi.02299-20 · Cited by 66
Leotta, S., Condorelli, A., Sciortino, R., Milone, G. A., Bellofiore, C., Garibaldi, B., Schininà, G., Spadaro, A., Cupri, A., & Milone, G. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11010253 · Cited by 64
Zhang, Y., Yeganeh, P. N., Zhang, H., Wang, S. Y., Li, Z., Gu, B., Lee, D.-J., Zhang, Z., Ploumakis, A., Shi, M., et al. (2024) · Nature Immunology · doi:10.1038/s41590-024-01932-8 · Cited by 64
ADAR1 , inosine and the immune sensing system: distinguishing self from non‐self
Liddicoat, B., Chalk, A. M., & Walkley, C. R. (2015) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1322 · Cited by 58
Mutated Chromatin Regulatory Factors as Tumor Drivers in Cancer
Koschmann, C. J., Núñez, F. J., Mendez, F., Brosnan‐Cashman, J. A., Meeker, A. K., Lowenstein, P. R., & Castro, M. G. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2301 · Cited by 60
Promising landscape for regulating macrophage polarization: epigenetic viewpoint
Zhou, D., Yang, K., Chen, L., Zhang, W., Xu, Z., Zuo, J., Jiang, H., & Luan, J. (2017) · Oncotarget · doi:10.18632/oncotarget.17027 · Cited by 64
Immunological effects of hypomethylating agents
Lindblad, K. E., Goswami, M., Hourigan, C. S., & Oetjen, K. A. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1346470 · Cited by 62
Nakanishi, Y., Durán, Á., L’Hermitte, A., Shelton, P. M., Nakanishi, N., Reina‐Campos, M., Huang, J., Soldevila, F., Baaten, B. J. G., Tauriello, D. V. F., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.09.013 · Cited by 59
Reactivation of Endogenous Retroelements in Cancer Development and Therapy
Ishak, C. A., & Carvalho, D. D. D. (2019) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030419-033525 · Cited by 59
Li, H., Zhang, Q., Shuman, L., Kaag, M. G., Raman, J. D., Merrill, S. B., DeGraff, D. J., Warrick, J. I., & Chen, G. (2020) · Scientific Reports · doi:10.1038/s41598-020-58351-6 · Cited by 60
Self-citationHong, S. H., Eun, J. W., Choi, S. K., Shen, Q., Choi, W. S., Han, J., Nam, S. W., & You, J. S. (2016) · Oncotarget · doi:10.18632/oncotarget.8701 · Cited by 60
Eckstein, M., Strissel, P. L., Strick, R., Weyerer, V., Wirtz, R. M., Pfannstiel, C., Wullweber, A., Lange, F., Erben, P., Stoehr, R., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000162 · Cited by 59
Self-citationChoi, H., Kwon, J., Cho, M. S., Sun, Y., Zheng, X., Wang, J., Bouker, K. B., Casey, J. L., Atkins, M. B., Toretsky, J. A., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3790 · Cited by 60
Demethylation and Up-Regulation of an Oncogene after Hypomethylating Therapy
Liu, Y., Kwon, J., Fabiani, E., Xiao, Z., Liu, Y. V., Follo, M. Y., Liu, J., Huang, H., Gao, C., Liu, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2119771 · Cited by 63
The Crossroads of Cancer Epigenetics and Immune Checkpoint Therapy
Micevic, G., Bosenberg, M., & Yan, Q. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0784 · Cited by 60
GSK-3484862 targets DNMT1 for degradation in cells
Chen, Q., Liu, B., Zeng, Y., Hwang, M. J., Dai, N., Junior, I. R. C., Estecio, M. R., Zhang, X., Santos, M. A., Chen, T., et al. (2023) · NAR Cancer · doi:10.1093/narcan/zcad022 · Cited by 58
The Application of Genome-Wide 5-Hydroxymethylcytosine Studies in Cancer Research
Thomson, J. P., & Meehan, R. R. (2016) · Epigenomics · doi:10.2217/epi-2016-0122 · Cited by 60
Management of myelodysplastic syndromes after failure of response to hypomethylating agents
Pérez, Á. G., & Bravo, G. M. (2019) · Therapeutic Advances in Hematology · doi:10.1177/2040620719847059 · Cited by 51
Ka, N., Lim, G. Y., Hwang, S., Kim, S.-S., & Lee, M. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.110138 · Cited by 61
Epigenetic Modulators and the New Immunotherapies
Dear, A. E. (2016) · New England Journal of Medicine · doi:10.1056/nejmcibr1514673 · Cited by 57
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 60
Do Human Endogenous Retroviruses Contribute to Multiple Sclerosis, and if So, How?
Morris, G., Maes, M. H. J., Murdjeva, M., & Puri, B. K. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1255-x · Cited by 60
Suppression of Transposable Elements in Leukemic Stem Cells
Colombo, A., Zubair, A., Thiagarajan, D., Nuzhdin, S. V., Triche, T. J., & Ramsingh, G. (2017) · Scientific Reports · doi:10.1038/s41598-017-07356-9 · Cited by 60
Epigenetic therapies in acute myeloid leukemia: where to from here?
Fennell, K. A., Bell, C. C., & Dawson, M. A. (2019) · Blood · doi:10.1182/blood.2019003262 · Cited by 60
Kawazu, M., Ueno, T., Saeki, K., Sax, N., Togashi, Y., Kanaseki, T., Chida, K., Kishigami, F., Sato, K., Kojima, S., et al. (2021) · Gastroenterology · doi:10.1053/j.gastro.2021.10.010 · Cited by 57
Precision Oncology, Signaling, and Anticancer Agents in Cancer Therapeutics
Advani, D., Sharma, S., Kumari, S., Ambasta, R. K., & Kumar, P. (2021) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621666210308101029 · Cited by 63
From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades
Zhao, X., Bao, Y., Meng, B., Xu, Z., Li, S., Wang, X., Hou, R., Ma, W., Liu, D., Zheng, J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.920021 · Cited by 58
Zhong, F., Lin, Y., Zhao, L., Yang, C., Ye, Y., & Shen, Z. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02292-0 · Cited by 58
Conventional chemotherapy: millions of cures, unresolved therapeutic index
Letai, A. G., & de Thé, H. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00778-4 · Cited by 58
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth
Turner, T. B., Meza‐Perez, S., Londoño, A. I., Katre, A. K., Lever, J. E. P., Smith, H. J., Forero, A., Norian, L. A., Straughn, J. M., Buchsbaum, D. J., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17395 · Cited by 58
Leung, K., Nguyen, A. N., Shi, T., Tang, L., Ni, X., Escoubet, L., MacBeth, K. J., DiMartino, J. F., & Wells, J. A. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813666116 · Cited by 56
HDACs and the epigenetic plasticity of cancer cells: target the complexity
Brancolini, C., Gagliano, T., & Minisini, M. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108190 · Cited by 55
Leveraging epigenetics to enhance the efficacy of immunotherapy
Licht, J. D., & Bennett, R. L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01100-x · Cited by 54
Balasubramanian, A., John, T., & Asselin-Labat, M.-L. (2022) · Biochemical Society Transactions · doi:10.1042/bst20210961 · Cited by 61
Tang, Y., Cui, G., Liu, H., Han, Y., Cai, C., Feng, Z., Shen, H., & Zeng, S. (2024) · 癌症：英文版 · doi:10.1002/cac2.12546 · Cited by 56
Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities
Wang, H., Niu, X., Jin, Z., Zhang, S., Fan, R., Xiao, H., & Hu, S. (2025) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03519-z · Cited by 72
Flotho, C., Sommer, S., & Lübbert, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.10.011 · Cited by 57
Vaccine therapy in hematologic malignancies
Avigan, D., & Rosenblatt, J. M. (2018) · Blood · doi:10.1182/blood-2017-11-785873 · Cited by 53
The role of endogenous retroviruses‐K in human cancer
Salavatiha, Z., Soleimani‐Jelodar, R., & Jalilvand, S. (2020) · Reviews in Medical Virology · doi:10.1002/rmv.2142 · Cited by 57
Epigenetic state determines inflammatory sensing in neuroblastoma
Wolpaw, A. J., Grossmann, L. D., Dessau, J. L., Dong, M. M., Aaron, B., Brafford, P. A., Volgina, D., Pascual‐Pasto, G., Rodríguez-García, A., Uzun, Y., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102358119 · Cited by 53
Zeiser, R., Beelen, D. W., Bethge, W. A., Bornhäuser, M., Bug, G., Burchert, A., Christopeit, M., Duyster, J., Finke, J., Gerbitz, A., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.01.016 · Cited by 56
Genome-wide repeat landscapes in cancer and cell-free DNA
Annapragada, A. V., Niknafs, N., White, J. R., Bruhm, D. C., Cherry, C., Medina, J. E., Adleff, V., Hruban, C., Mathios, D., Foda, Z. H., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj9283 · Cited by 60
Lee, J. J., & Chu, E. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.06.004 · Cited by 55
Lee, V., Wang, J., ZAHURAK, M. L., Gootjes, E. C., Verheul, H. M. W., Parkinson, R. M., Kerner, Z. J., Sharma, A. R., Rosner, G. L., Jesus‐Acosta, A. D., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0421 · Cited by 54
Self-citationMITF Expression Predicts Therapeutic Vulnerability to p300 Inhibition in Human Melanoma
Kim, E. J., Zucconi, B. E., Wu, M., Nocco, S. E., Meyers, D. J., McGee, J. S., Venkatesh, S., Cohen, D. L., Gonzalez, E. C., Ryu, B., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2331 · Cited by 54
Metadata
- Authors
- Chiappinelli, K. B., Strissel, P. L., Desrichard, A., Li, H., Henke, C., Akman, B., Hein, A., Rote, N. S., Cope, L. M., Snyder, A., Makarov, V., Buhu, S., Slamon, D. J., Wolchok, J. D., Pardoll, D. M., Beckmann, M. W., Zahnow, C. A., Merghoub, T., Chan, T. A., Baylin, S. B., & Strick, R.
- Affiliations
- Johns Hopkins University (US)
- Universitätsklinikum Erlangen (DE)
- Memorial Sloan Kettering Cancer Center (US)
- Case Western Reserve University (US)
- University of California, Los Angeles (US)
- Corresponding author
- Baylin, Stephen B.
- Strick, Reiner
- ORCID
- Venue
- Cell
- Publisher
- Elsevier BV
- Published
- 2015-08
- Volume
- 162
- Issue
- 5
- Pages
- 974-986
- ISSN
- 0092-8674 (ISSN-L)
- PMC
- PMC4556003
- OpenAlex
- W1953890763
- Cited by
- 2,022
- References
- 94
- Citations by year
- 2026: 193 · 2025: 188 · 2024: 211 · 2023: 209 · 2022: 225 · 2021: 250 · 2020: 184 · 2019: 163 · 2018: 161 · 2017: 133 · 2016: 93 · 2015: 10
- FWCI
- 65.10
- Type
- journal article
- Language
- en
- Update notices
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cell (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (P50CA058184, CA058184, F32CA183214, P30CA008748)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Keywords
- hypomethylating agents, DNA methylation, type I interferon response, double-stranded RNA sensing, endogenous retroviruses, ovarian cancer, melanoma, TLR3, MAVS, interferon-beta, apoptosis, immune checkpoint therapy, CTLA-4, tumor immune microenvironment, epigenetic reprogramming
- MeSH terms
- Animals, Azacitidine, Female, Humans, Immunotherapy, Interferon Type I, Lung Neoplasms, Melanoma, Mice, Inbred C57BL, Ovarian Neoplasms, RNA, Double-Stranded, DNA Modification Methylases, DNA Methylation, Endogenous Retroviruses, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
